1 The safety and efficacy of Remicade was supported by a multi-center, randomized, open-label study in 60 children ages 6 years to 17 years with moderately to severely active UC.

2 Remicade belongs to a class of drugs called tumor necrosis factor (TNF) blockers.

3 Also, Schering-Plough Corp's arthritis treatment Remicade carries a warning due to increased risk of infections and rare cases of a type of lymphoma.

4 Remicade reduces signs and symptoms of UC and induces and maintains clinical remission in these patients.

5 Remicade carries a Boxed Warning for risk of serious infections and cancer.

6 The most common side effects of Remicade are worsening of UC, upper respiratory infections, infusion-related reactions,[] and headache.

7 The introduction of the first anti-TNF drug, infliximab (Remicade), revolutionized the treatment of Crohn's disease, wrote Dr.

8 Anemia medicine Procrit, arthritis treatment Remicade and attention deficit disorder drug Concerta all fell short of analyst targets for the quarter.

9 Children should have all of their vaccines brought up to date before starting treatment with Remicade and should not receive live vaccines while taking Remicade.

10 Allergic reactions, some severe, hae been reported during or after infusions with REMICADE.

11 After 26 weeks of treatment, patients getting the combination had a 57% chance of disease remission, compared to 44% of those getting Remicade alone and to 30% of those getting azathioprine alone.

12 These patients generally require treatment with systemic medications like the drugs methotrexate and cyclosporine or newer biologics such as Enbrel, Remicade, and Humira.

13 Among these patients, 69% achieved remission with the combination treatment compared to 57% of those on Remicade alone and to 28% of those on azathioprine alone.